The immune suppressive function of transforming growth factor-β (TGF-β) in human diseases

Growth Factors

Volumn 33, Issue 2, 2015, Pages 92-101

  Sheng, Jingyi ^a   Chen, Weisan ^b   Zhu, Hong Jian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

Autoimmune diseases; Cancer; Immune suppression; TGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; CANCER VACCINE; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER IMMUNIZATION; CELL DIFFERENTIATION; DENDRITIC CELL; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TH17 CELL; ADAPTIVE IMMUNITY; ANIMAL; CHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNATE IMMUNITY; MOUSE;

ADAPTIVE IMMUNITY; ANIMALS; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CANCER VACCINES; CELL DIFFERENTIATION; DENDRITIC CELLS; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MICE; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84929312521     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2015.1010645     Document Type: Article

References (127)

1. Ahn J-Y, Kim M-H, Lim M-J, Park S, Lee S-L-O, Yun Y-S, Song J-Y. 2011. The inhibitory effect of ginsan on TGF-b mediated fibrotic process. J Cell Physiol 226:1241-1247.
2. Allen JB, Manthey CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM. 1990. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta. J Exp Med 171:231-247.
3. Anaya JM. 2012. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev 11:781-784.
4. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGFb activation. J Cell Sci 116:217-224.
5. Bakkebø M, Huse K, Hilden VI, Smeland EB, Oksvold MP. 2010. TGF-b-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK. BMC Immunol 11:57-57.
6. Becker-Merok A, Eilertsen GØ, Nossent JC. 2010. Levels of transforming growth factor-b are low in systemic lupus erythematosus patients with active disease. J Rheumatol 37:2039-2045.
7. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238.
8. Bournia VKK, Vlachoyiannopoulos PG, Selmi C, Moutsopoulos HM, Gershwin ME. 2009. Recent advances in the treatment of systemic sclerosis. Clin Rev Allerg Immunol 36:176-200.
9. Byung-Gyu K, Cuiling L, Wenhui Q, Mamura M, Kasperczak B, Anver M, Wolfraim L, et al. 2006. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441:1015-1019.
10. Cazac BB, Roes J. 2000. TGF-b receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13:443-451.
11. Chang H, Brown CW, Matzuk MM. 2002. Genetic analysis of the mammalian transforming growth factor-b superfamily. Endocrine Rev 23:787-823.
12. + influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med 197: 1689-1699.
13. + regulatory T cells by TGF-b induction of transcription factor Foxp3. J Exp Med 198:1875-1886.
14. Chen Y-G 2009. Endocytic regulation of TGF-b signaling. Cell Res 19: 58-70.
15. Chong MM, Rasmussen JP, Rudensky AY, Littman DR. 2008. The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med 205:2005-2017.
16. Chu CQ, Field M, Abney E, Zheng RQ, Allard S, Feldmann M, Maini RN. 1991. Transforming growth factor-b1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 86: 380-386.
17. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. 2010. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-oncology 12:7-13.
18. Crotty S. 2011. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29:621-663.
19. Däien CI, Fabre S, Rittore C, Soler S, Däien V, Tejedor G, Cadart D, et al. 2012. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine 79:471-475.
20. Daniel P, Allison S, Yiming Y, Ying-Yi Z, Laurence M. 2011. Murine models of systemic lupus erythematosus. J Biomed Biotech 2011:1-9.
21. + Foxp3~effector T cells. Nat Immunol 9:1347-1355.
22. +) T regulatory cells. J Immunol 178:4022-4026.
23. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, et al. 2007. Recombinant human anti-transforming growth factor b1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56:323-333.
24. Egawa T, Kreslavsky T, Littman DR, von Boehmer H. 2008. Lineage diversion of T cell receptor transgenic thymocytes revealed by lineage fate mapping. PLoS One 3:e1512.
25. Egawa T, Littman DR. 2008. ThPOK acts late in specification of the helper T cell lineage and suppresses Runx-mediated commitment to the cytotoxic T cell lineage. Nat Immunol 9:1131-1139.
26. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. 2010. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10:554-567.
27. Galliher AJ, Schiemann WP 2007. Src phosphorylates Tyr(284) in TGF-b type II receptor and regulates TGF-b stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 67:3752-3758.
28. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, et al. 2010. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467:967-971.
29. Goodnow CC, Cyster JG, Hartley SB, Bell SE, Cooke MP, Healy JI, Akkaraju S, et al. 1995. Self-tolerance checkpoints in B lymphocyte development. Adv Immunol 59:279-368.
30. Gorelik L, Constant S, Flavell RA. 2002. Mechanism of transforming growth factor b-induced inhibition of T helper type 1 differentiation. J Exp Med 195:1499-1505.
31. Gorelik L, Fields PE, Flavell RA. 2000. Cutting edge: TGF-b inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 165:4773-4777.
32. Govinden R, Bhoola KD. 2003. Genealogy, expression, and cellular function of transforming growth factor-b. Pharmacol Ther 98: 257-265.
33. Gu AD, Wang Y, Lin L, Zhang SS, Wan YY. 2012. Requirements of transcription factor Smad-dependent and -independent TGF-beta signaling to control discrete T-cell functions. Proc Natl Acad Sci USA 109:905-910.
34. Guerder S, Picarella DE, Linsley PS, Flavell RA. 1994. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor a leads to autoimmunity in transgenic mice. Proc Natl Acad Sci USA 91:5138-5142.
35. Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO. 2011. Autocrine transforming growth factor-b1 promotes in vivo Th17 cell differentiation. Immunity 34:396-408.
36. Habibagahi M, Habibagahi Z, Jaberipour M, Aghdashi A. 2011. Quantification of regulatory T cells in peripheral blood of patients with systemic lupus erythematosus. Rheumatol Int 31:1219-1225.
37. Hardy RR. 2006. B-1 B cell development. J Immunol 177:2749-2754.
38. Haritunians T, Gueller S, O'Kelly J, Ilaria Jr R, Koeffler HP. 2008. Novel acyl sulfonamide LY573636-sodium: Effect on hematopoietic malignant cells. Oncol Rep 20:1237-1242.
39. Harris Jr ED. 1990. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322:1277-1289.
40. Hatton RD. 2011. TGF-beta in Th17 cell development: The truth is out there. Immunity 34:288-290.
41. Heath VL, Murphy EE, Crain C, Tomlinson MG, O'Garra A. 2000. TGF-b1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression. Eur J Immunol 30:2639-2649.
42. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. 2001. The TGF b receptor activation process: An inhibitor-to substrate-binding switch. Mol Cell 8:671-682.
43. Ichiyama K, Sekiya T, Inoue N, Tamiya T, Kashiwagi I, Kimura A, Morita R, et al. 2011. Transcription factor Smad-independent T helper 17 cell induction by transforming-growth factor-b is mediated by suppression of eomesodermin. Immunity 34:741-754.
44. Ihn H. 2008. Autocrine TGF-b signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 49:103-113.
45. Ikushima H, Miyazono K. 2010. TGFb signalling: A complex web in cancer progression. Nat Rev Cancer 10:415-424.
46. Ishigame H, Mosaheb MM, Sanjabi S, Flavell RA. 2013a. Truncated form of TGF-betaRII, but not its absence, induces memory CD8+ T cell expansion and lymphoproliferative disorder in mice. J Immunol 190:6340-6350.
47. Ishigame H, Zenewicz LA, Sanjabi S, Licona-Limon P, Nakayama M, Leonard WJ, Flavell RA. 2013b. Excessive Th1 responses due to the absence of TGF-beta signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc Natl Acad Sci USA 110: 6961-6966.
48. Ivanov, II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR. 2008. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4:337-349.
49. Jin T, Almehed K, Carlsten H, Forsblad-d'Elia H. 2012. Decreased serum levels of TGF-b1 are associated with renal damage in female patients with systemic lupus erythematosus. Lupus 21:310-318.
50. Johnson LDS, Jameson SC. 2012. TGF-beta sensitivity restrains CD8+T cell homeostatic proliferation by enforcing sensitivity to IL-7 and IL-15. PLoS One 7:e42268.
51. Kao H, Lin J, Littman DR, Shaw AS, Allen PM. 2008. Regulated movement of CD4 in and out of the immunological synapse. J Immunol 181:8248-8257.
52. Kappler JW, Roehm N, Marrack P. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273-280.
53. Kee BL, Rivera RR, Murre C. 2001. Id3 inhibits B lymphocyte progenitor growth and survival in response to TGF-b. Nat Immunol 2:242-247.
54. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng GJ, Haas A, et al. 2008. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 68:10247-10256.
55. Kirkwood JM, Gonzalez R, Reintgen D, Clingan PR, McWilliams RR, de Alwis DP, Zimmermann A, et al. 2011. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer 117: 4732-4739.
56. + thymocytes. Nature 333:742-746.
57. Konstantine IV, Roubina Ch A, Dimitrios KK, Eleftherios S, Sotirios T. 2011. TGF-b/BMPs: Crucial crossroad in neural autoimmune dis orders. Neurochem Int 59:542-550.
58. Kuwahara M, Yamashita M, Shinoda K, Tofukuji S, Onodera A, Shinnakasu R, Motohashi S, et al. 2012. The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-beta and suppresses T(H)2 differentiation. Nat Immunol 13:778-786.
59. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233-240.
60. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. 2005. Transforming growth factor-b controls T helper type 1 cell development through regulation of natural killer cell interferon-g. Nat Immunol 6:600-607.
61. Lee JC, Lee KM, Kim DW, Heo DS. 2004. Elevated TGF-b1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172:7335-7340.
62. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, Wu C, et al. 2012. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 13:991-999.
63. Li MO, Sanjabi S, Flavell RA. 2006a. Transforming growth factor-b controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25:455-471.
64. Li MO, Wan YY, Sanjabi S, Robertson AKL, Flavell RA. 2006b. Transforming growth factor-b regulation of immune responses. Annu Rev Immunol 24:99-146.
65. Li MO, Wan YSY, Flavell RA. 2007. T cell-produced transforming growth factor-b1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26:579-591.
66. Li Yang YP, Haeold LM. 2010. TGF-b and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31:220-227.
67. Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W. 2008. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol 9:632-640.
68. Lotz M, Kekow J, Carson DA. 1990. Transforming growth factor-b and cellular immune responses in synovial fluids. J Immunol 144: 4189-4194.
69. Lucas PJ, Kim SJ, Mackall CL, Telford WG, Chu YW, Hakim FT, Gress RE. 2006. Dysregulation of IL-15-mediated T-cell homeostasis in TGF-b dominant-negative receptor transgenic mice. Blood 108: 2789-2795.
70. Lucas PJ, Kim SJ, Melby SJ, Gress RE. 2000. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor b II receptor. J Exp Med 191:1187-1196.
71. Luci C, Reynders A, Ivanov, II, Cognet C, Chiche L, Chasson L, Hardwigsen J, et al. 2009. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol 10:75-82.
72. Mandy JM, Daniel JC. 2008. Th17 cell differentiation: The long and winding road. Immunity 28:445-453.
73. Manel N, Unutmaz D, Littman DR. 2008. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9:641-649.
74. H17 lineage. Nature 441:231-234.
75. + regulatory T cells. J Exp Med 201:1061-1067.
76. Massague J. 1998. TGF-b signal transduction. Annu Rev Biochem 67: 753-791.
77. Massagué J. 2008. TGFb in Cancer. Cell 134:215-230.
78. McCarron MJ, Marie JC. 2014. TGF-beta prevents T follicular helper cell accumulation and B cell autoreactivity. J Clin Invest 124: 4375-4386.
79. Ming OL, Richard AF. 2008. TGF-b: A master of all T cell trades. Cell 134:392-404.
80. Mu YB, Gudey SK, Landstrom M. 2012. Non-Smad signaling pathways. Cell Tissue Res 347:11-20.
81. Munoz O, Fend F, de Beaumont R, Husson H, Astier A, Freedman AS. 2004. TGFb-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia 18:2015-2025.
82. Murphy KM, Reiner SL. 2002. The lineage decisions of helper T cells. Nat Rev Immunol 2:933-944.
83. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S. 2008. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 373: 286-291.
84. Norbert G, David HB. 2007. Gender as risk factor for autoimmune diseases. J Autoimmun 28:1-6.
85. Pang Y, Gara SK, Achyut BR, Li Z, Yan HH, Day CP, Weiss JM, et al. 2013. TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer Discov 3:936-951.
86. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, Wang Y, et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141.
87. Penafuerte C, Bautista-Lopez N, Bouchentouf M, Birman E, Forner K, Galipeau J. 2011. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J Immunol 186:6933-6944.
88. Penafuerte C, Ng S, Bautista-Lopez N, Birman E, Forner K, Galipeau J. 2012. B effector cells activated by a chimeric protein consisting of IL-2 and the ectodomain of TGF-beta receptor II induce potent antitumor immunity. Cancer Res 72:1210-1220.
89. Pohlers D, Beyer A, Koczan D, Wilhelm T, Thiesen HJ, Kinne RW. 2007. Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 9:R59.
90. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. 2008.Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 205:2125-2138.
91. Ramalingam R, Larmonier CB, Thurston RD, Midura-Kiela MT, Zheng SG, Ghishan FK, Kiela PR. 2012. Dendritic cell-specific disruption of TGF-beta receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J Immunol 189:3878-3893.
92. Raz E, Dudler J, Lotz M, Baird SM, Berry CC, Eisenberg RA, Carson DA. 1995. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 4:286-292.
93. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531-562.
94. Scandella E, Bolinger B, Lattmann E, Miller S, Favre S, Littman DR, Finke D, et al. 2008. Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat Immunol 9:667-675.
95. Schmitt N, Liu Y, Bentebibel SE, Munagala I, Bourdery L, Venuprasad K, Banchereau J, Ueno H.2014. The cytokine TGF-beta co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. Nat Immunol 15:856-865.
96. Shashi A, Ameeta P, Padmaja M. 2012. Sex differences and genomics in autoimmune diseases. J Autoimmun 38:J254-J265.
97. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA. 2011. Latent TGF-beta structure and activation. Nature 474:343-349.
98. Shi YG, Massague J. 2003. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 113:685-700.
99. Simon GR, Ilaria Jr RL, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, et al. 2011. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol 68:1233-1241.
100. Stephen TL, Rutkowski MR, Allegrezza MJ, Perales-Puchalt A, Tesone AJ, Svoronos N, Nguyen JM, et al. 2014. Transforming growth factor beta-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 41:427-439.
101. Surh CD, Sprent J. 2012. TGF-beta puts the brakes on homeostatic proliferation. Nat Immunol 13:628-630.
102. Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov, II, Littman DR, O'Shea JJ. 2009. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 206:35-41.
103. Tassi I, Cella M, Presti R, Colucci A, Gilfillan S, Littman DR, Colonna M. 2008. NK cell-activating receptors require PKC-theta for sustained signaling, transcriptional activation, and IFN-gamma secretion. Blood 112:4109-4116.
104. Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonnin S, McPherson JM, Berzofsky JA. 2009. Synergistic enhancement of CD8(+) T cell-mediated tumor vaccine efficacy by an anti-trans-forming growth factor-b monoclonal antibody. Cancer Res 15: 6560-6569.
105. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen WJ, et al. 2003. Transforming growth factor-b production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J Exp Med 198:1472-1752.
106. Thiery JP. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454.
107. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. 1992. Involvement of endogenous tumor necrosis factor a and transforming growth factor b during induction of collagen type II arthritis in mice. Proc Nat Acad Sci USA 89:7375-7379.
108. Tsuji M, Suzuki K, Kitamura H, Maruya M, Kinoshita K, Ivanov, II, Itoh K, et al. 2008. Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. Immunity 29:261-271.
109. Veldhoen M, Hocking RJ, Flavell RA, Stockinger B. 2006. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 7:1151-1156.
110. Wahl SM. 1994. Transforming growth factor b: The good, the bad, and the ugly. J Exp Med 180:1587-1590.
111. Wahl SM, Allen JB, Costa GL, Wong HL, Dasch JR. 1993. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor-b. J Exp Med 177:225-230.
112. Wahl SM, Wen J, Moutsopoulos N. 2006. TGF-b: A mobile purveyor of immune privilege. Immunol Rev 213:213-227.
113. Werner F, Jain MK, Feinberg MW, Sibinga NES, Pellacani A, Wiesel P, Chin MT, et al. 2000. Transforming growth factor-b1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem 275: 36653-36658.
114. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. 1994. Mechanism of activation of TGF-b receptor. Nature 370:341-347.
115. + regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci USA 103:2758-2763.
116. + regulatory T cells. Transplantation 93:580-588.
117. + myeloid cells that promote metastasis. Cancer Cell 13:23-35.
118. Yang L, Moses HL. 2008. Transforming growth factor b: Tumor suppressor or promoter? Are host immune cells the answer? Cancer Res 68:9107-9111.
119. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-b. EMBO J 18:1280-1291.
120. Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, Longenecker G, et al. 1996. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 87: 1439-1445.
121. Yoshimura A, Wakabayashi Y, Mori T. 2010. Cellular and molecular basis for the regulation of inflammation by TGF-b. J Biochem 147: 781-792.
122. Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, Anguiano E, et al. 2013. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-beta. Immunity 38:818-830.
123. Zhang JX, Diehl GE, Littman DR. 2008. Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PLoS One 3:e2035.
124. Zhang N, Bevan MJ. 2012. TGF-beta signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat Immunol 13:667-673.
125. Zhou L, Lopes JE, Chong MM, Ivanov, II, Min R, Victora GD, Shen Y, et al. 2008. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453: 236-240.
126. Zhu HJ, Burgess AW. 2001. Regulation of transforming growth factor-beta signaling. Mol Cell Biol Res Commun 4:321-330.
127. Zi Z, Chapnick DA, Liu X. 2012. Dynamics of TGF-b/Smad signaling. FEBS Lett 586:1921-1928.